Status:
COMPLETED
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Lead Sponsor:
Corcept Therapeutics
Conditions:
Major Depressive Disorder
Psychotic Disorders
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physic...
Eligibility Criteria
Inclusion
- Individuals eligible for enrollment into this study are male and female adult patients who:
- Are 18 to 75 years of age
- Have a diagnosis of major depressive disorder with psychotic features (DSM-IV 296.24 or 296.34)
- Are able to provide written informed consent.
Exclusion
- Individuals not eligible to be enrolled into the study are those who:
- Have a major medical problem
- Have previously participated in a CORLUX (C-1073, mifepristone) clinical trial
- Have a history of an allergic reaction to CORLUX (C-1073, mifepristone).
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
443 Patients enrolled
Trial Details
Trial ID
NCT00128479
Start Date
September 1 2004
End Date
January 1 2007
Last Update
February 15 2012
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
K&S Research Services
Little Rock, Arkansas, United States, 72201
2
Center for Emotional Fitness
Cerritos, California, United States, 90703
3
Harbor Medical Associates, Inc.
Fountain Valley, California, United States, 92708
4
Synergy Clinical Research Center
National City, California, United States, 91950